Lexicon Pharmaceuticals Inc. (LXRX) Given “Buy” Rating at Wedbush
Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX)‘s stock had its “buy” rating reissued by Wedbush in a research note issued to investors on Sunday. They currently have a $33.00 price objective on the biopharmaceutical company’s stock. Wedbush’s price target suggests a potential upside of 84.87% from the company’s current price.
Other research analysts have also recently issued research reports about the company. Zacks Investment Research cut Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, July 6th. Needham & Company LLC reiterated a “buy” rating on shares of Lexicon Pharmaceuticals in a research report on Thursday, August 11th. Citigroup Inc. began coverage on Lexicon Pharmaceuticals in a research report on Tuesday, August 2nd. They set a “buy” rating and a $21.00 price objective on the stock. Stifel Nicolaus increased their price objective on Lexicon Pharmaceuticals from $25.00 to $26.00 and gave the stock a “buy” rating in a research report on Friday, August 5th. Finally, Cowen and Company reiterated a “hold” rating on shares of Lexicon Pharmaceuticals in a research report on Friday. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and four have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $20.36.
Lexicon Pharmaceuticals (NASDAQ:LXRX) opened at 17.85 on Friday. The firm’s market cap is $1.85 billion. Lexicon Pharmaceuticals has a 12 month low of $7.65 and a 12 month high of $19.19. The company’s 50-day moving average is $15.54 and its 200 day moving average is $13.70.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/11/lexicon-pharmaceuticals-inc-lxrx-given-buy-rating-at-wedbush.html
Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.04. Lexicon Pharmaceuticals had a negative return on equity of 9.03% and a negative net margin of 13.42%. The business had revenue of $20.10 million for the quarter, compared to analysts’ expectations of $12.36 million. During the same quarter in the prior year, the business earned ($0.27) EPS. The firm’s revenue for the quarter was up 5186.8% on a year-over-year basis. Equities research analysts expect that Lexicon Pharmaceuticals will post ($1.54) EPS for the current fiscal year.
Several hedge funds and institutional investors recently modified their holdings of LXRX. Capital Fund Management S.A. bought a new position in shares of Lexicon Pharmaceuticals during the second quarter worth approximately $283,000. American Century Companies Inc. bought a new position in shares of Lexicon Pharmaceuticals during the second quarter worth approximately $2,194,000. Falcon Point Capital LLC boosted its position in shares of Lexicon Pharmaceuticals by 3.5% in the second quarter. Falcon Point Capital LLC now owns 287,809 shares of the biopharmaceutical company’s stock worth $4,130,000 after buying an additional 9,816 shares during the last quarter. Old Mutual Global Investors UK Ltd. bought a new position in shares of Lexicon Pharmaceuticals during the second quarter worth approximately $257,000. Finally, Acadian Asset Management LLC bought a new position in shares of Lexicon Pharmaceuticals during the second quarter worth approximately $863,000.
Lexicon Pharmaceuticals Company Profile
Lexicon Pharmaceuticals, Inc (Lexicon) is a biopharmaceutical company. The Company focuses on the development of treatments for human disease. The Company is engaged in the development of two drug candidates: telotristat etiprate (LX1032) and sotagliflozin (LX4211). The Company’s telotristat etiprate, is an orally delivered small molecule drug candidate, as a treatment for carcinoid syndrome.
Receive News & Ratings for Lexicon Pharmaceuticals Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Lexicon Pharmaceuticals Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.